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SUMMARY

24
This paper aimed to identify the dietary and non-dietary determinants of docosahexaenoic acid 25 (DHA) levels in umbilical cord blood at delivery. DHA was measured in cord blood plasma consumed over the course of pregnancy and gestational age at delivery individually explained 21% 32 and 16% respectively of the variation in DHA abundance in the cord blood plasma phospholipids at 33 delivery, but no other clinical or life-style factors explored in this study could account for >2% of 34 the variation. Indeed, more than 65% of the variation remained unaccounted for even when all 35 factors were included in the analysis. These data suggest that factors other than maternal DHA 36 intake have an important role in determining cord blood DHA concentrations at delivery, and may 37 at least partially explain the variation in the response of infants to maternal DHA supplementation 38 reported in published trials.
INTRODUCTION
44
The omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA), docosahexanoic acid (DHA, 45 22:6n-3) plays a critical role in development, and an adequate supply of this fatty acid during the 46 period of rapid growth in late fetal and early postnatal life is essential for optimal development of a 47 number of key organ systems [1, 2] . The accumulation of DHA in fetal tissues occurs 48 predominately during the last trimester of pregnancy and continues through the first year of life.
49
Studies that have determined fatty acid abundance in the umbilical cord blood at delivery have 50 shown that levels of n-3 LCPUFA, in particular DHA, are higher in the umbilical cord blood (a 51 marker of fetal supply) compared to the levels of the equivalent fatty acids in the maternal 52 circulation [1, 3] . This apparent biomagnification is reported to be a result of both preferential 53 transfer of DHA by the placenta and fetal uptake/metabolism to ensure that the fetal supply of DHA 54 is maintained even when maternal dietary intake is low [3] .
56
While the fetus has the capacity for DHA synthesis from the 18-carbon precursor, alpha-linoleic 57 acid (ALA) and DHA metabolism, the prevailing view is that the principal determinant of DHA 58 supply to the developing fetus in healthy pregnancies is the DHA intake of the mother [4] [5] [6] .
59
However, studies that have measured cord blood fatty acids have also consistently demonstrated a 60 high degree of heterogeneity in the DHA content of cord blood phospholipids between individual 61 women, even when DHA intake is similar [5, 7, 8] . This has led to the suggestion that factors other 62 than nutritional intake also play an important role in determining cord blood DHA content, and Women were asked to take their assigned capsules daily from study entry until birth, and to return Table 1 . than the limit of detection (0.05%) were allocated a set value of 0.025% (half the limit of detection).
138
The abundance of all fatty acids was expressed as a percentage of total fatty acids in the sample.
140
Statistical Analyses
141
Cord plasma phospholipid fatty acid concentrations were compared between treatment groups using 142 t-tests. Concentrations were log transformed prior to analysis to achieve normality, with the 143 exception of total saturates, arachidonic acid (AA, 20:4 n-6) and total n-6 PUFA, which did not 144 require any transformation. The fatty acid composition of the cord blood plasma phospholipids for the DHA and control groups 164 is shown in Table 2 . Independent of treatment group, AA and DHA were the most abundant n-6 165 and n-3 LCPUFA in the cord blood phospholipids. Cord blood from DHA-supplemented mothers 166 had significantly higher proportions of the three principal n-3 LCPUFA, EPA, docosapentaenoic 167 acid (DPA, 22:5 n-3) and DHA) and a significantly lower proportion of AA compared with cord 168 blood from mothers in the control group (Table 2) . The cord blood from the mothers in the DHA 169 group also contained a slightly (40%) higher proportion of LA compared with the control group.
170
There was no evidence of a difference in the proportion of total saturated or total monounsaturated 171 fatty acids in the cord blood plasma phospholipids between the DHA and control groups. As expected, supplementing pregnant women with ~800mg of DHA and 100mg EPA per day in the 227 second half of pregnancy resulted in a significant increase in the n-3 LCPUFA abundance in cord 228 blood phospholipids at the time of delivery. The relative increase in cord-blood DHA abundance in 229 the supplemented group was ~23%, which is comparable with the results of other studies of 230 maternal DHA supplementation using similar doses of DHA [7, 15] . The increase in n-3 LCPUFA 231 levels in the cord blood of supplemented women was associated with a corresponding decrease in 232 the n-6 PUFA content. The decrease in total n-6 PUFA concentrations was almost entirely 233 accounted for by a decrease in the abundance of AA in the supplemented group, the magnitude of
234
which was approximately equal to the increase in total n-3 LPCUFA (EPA, DPA, DHA)
235
abundance. This is not unexpected given the competition which exists between the n-3 LCPUFA
236
and AA for incorporation into plasma phospholipids, such that relative increases in the availability 237 of n-3 LCPUFA reduce the incorporation of AA into this lipid fraction [16, 17] . The only identified variable other than n-3 LCPUFA supplement intake to explain an appreciable 271 amount of the variation in cord blood DHA was gestational age at delivery, and this accounted for a in cord blood DHA content.
282
There was still considerable heterogeneity, however, in cord blood DHA at any given gestational 
